TLR4 and lobular neoplasia: For patients with hormone-dependent or resistant LN, JZD may be used as an adjunctive therapy to reduce the dosage of glucocorticoids by inhibiting the TLR4/MAPK pathway; for patients at subclinical stage, the early application of JZD may block the ‘inflammation-fibrosis’ vicious cycle and slow down the deterioration of renal function.